Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

医学 帕妥珠单抗 内科学 曲妥珠单抗 临床终点 不利影响 肿瘤科 实体瘤疗效评价标准 贫血 队列 危险系数 癌症 进行性疾病 临床试验 置信区间 乳腺癌 疾病
作者
Timothy Lewis Cannon,Michael Rothe,Pam K. Mangat,Elizabeth Garrett‐Mayer,Vi K. Chiu,Jimmy J. Hwang,Namrata Vijayvergia,Olatunji B. Alese,Elie G. Dib,Herbert L. Duvivier,Kelsey Klute,Vaibhav Sahai,Eugene Ahn,Pablo M. Bedano,Deepti Behl,Sarah Sinclair,Ramya Thota,Walter J. Urba,Eddy S. Yang,Gina N. Grantham
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (27): 3228-3237 被引量:6
标识
DOI:10.1200/jco.23.02078
摘要

PURPOSE Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with biliary tract cancer (BTC) with ERBB2/3 amplification, overexpression, or mutation treated with pertuzumab plus trastuzumab are reported. METHODS Eligible patients had advanced BTC, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with ERBB2/3 alterations, and a lack of standard treatment options. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) or stable disease of at least 16+ weeks duration (SD16+) according to RECIST v1.1. Secondary end points included OR, progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS Twenty-nine patients were enrolled from February 2017 to January 2022, and all had advanced BTC with an ERBB2/3 alteration. One patient was not evaluable for efficacy. One complete response, eight partial responses, and two SD16+ were observed for DC and OR rates of 40% (90% CI, 27 to 100) and 32% (95% CI, 16 to 52), respectively. The null hypothesis of 15% DC rate was rejected ( P = .0015). Four patients had at least one grade 3 adverse event (AE) or serious AE at least possibly related to treatment: anemia, diarrhea, infusion-related reaction, and fatigue. CONCLUSION Pertuzumab plus trastuzumab met prespecified criteria to declare a signal of activity in patients with BTC and ERBB2/3 amplification, overexpression, or mutation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
wanci应助赵雪萌采纳,获得10
2秒前
科研果发布了新的文献求助10
3秒前
3秒前
3秒前
5秒前
6秒前
6秒前
Amon完成签到 ,获得积分10
6秒前
Lillian完成签到,获得积分10
7秒前
桐桐应助畅快的涵蕾采纳,获得30
8秒前
胡翔完成签到,获得积分10
9秒前
9秒前
nyfz2002发布了新的文献求助10
9秒前
9秒前
Phung完成签到,获得积分20
10秒前
科研通AI5应助尔尔采纳,获得10
10秒前
佩佩发布了新的文献求助10
11秒前
赵雪萌完成签到,获得积分10
11秒前
Marilyn完成签到,获得积分10
12秒前
小朱佩奇发布了新的文献求助10
13秒前
情怀应助舒适的尔容采纳,获得10
14秒前
郭囯完成签到,获得积分10
15秒前
缥缈的背包完成签到,获得积分10
16秒前
七七完成签到 ,获得积分10
17秒前
fugu0完成签到,获得积分10
19秒前
Zenobia完成签到,获得积分10
21秒前
朱马大完成签到,获得积分10
21秒前
丘比特应助小兑采纳,获得10
21秒前
量子星尘发布了新的文献求助10
21秒前
22秒前
科研果完成签到,获得积分10
22秒前
22秒前
23秒前
共享精神应助LLL采纳,获得10
26秒前
一顾千年完成签到,获得积分10
26秒前
27秒前
豆豆完成签到,获得积分10
27秒前
Rory完成签到 ,获得积分10
28秒前
快乐修勾完成签到 ,获得积分10
29秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969884
求助须知:如何正确求助?哪些是违规求助? 3514604
关于积分的说明 11174901
捐赠科研通 3249928
什么是DOI,文献DOI怎么找? 1795149
邀请新用户注册赠送积分活动 875599
科研通“疑难数据库(出版商)”最低求助积分说明 804891